DCF Valuation
Syra Health Corp. Class A Common Stock (SYRA) DCF Valuation — Is SYRA overvalued?
The estimated DCF fair value of one Syra Health Corp. Class A Common Stock (SYRA) share is $0.16. Compared to the current market price of $0.73, the stock is overvalued by 77.9%.
DCF fair value
$0.16
Market price
$0.73
Upside / downside
−77.9%
Prefer the inverse question? See what growth rate the market is pricing into SYRA →
Syra Health Corp. Class A Common Stock (SYRA) DCF valuation FAQ
What is the DCF fair value of Syra Health Corp. Class A Common Stock (SYRA)?
The discounted-cash-flow model estimates the intrinsic fair value of one Syra Health Corp. Class A Common Stock (SYRA) share at $0.16, based on a 10-year projection of its cash flows converging to Damodaran industry averages.
Is Syra Health Corp. Class A Common Stock (SYRA) overvalued or undervalued?
Against the current market price of $0.73, the DCF fair value of $0.16 implies SYRA is overvalued by 77.9%.
How is the SYRA DCF value calculated?
It is a 10-year discounted-cash-flow estimate built from Syra Health Corp. Class A Common Stock's reported fundamentals, with terminal assumptions anchored to Damodaran NYU industry datasets. The market price refreshes daily; the DCF fair value updates when Syra Health Corp. Class A Common Stock files a new quarterly or annual report.
How this SYRA valuation is built
The model projects ten years of Syra Health Corp. Class A Common Stock's free cash flow to the firm and discounts each year at its own cost of capital. Rather than assuming today's growth and margins persist forever, a moat-scoring step — weighing Syra Health Corp. Class A Common Stock's ROIC-versus-WACC spread, gross-margin trend, and reinvestment efficiency — decides how many years the business holds its edge before its economics mean-revert toward the Damodaran NYU benchmarks for its industry.
WACC is rebuilt each year from an unlevered-then-relevered beta and the company's evolving capital structure; terminal value uses the Gordon growth model with a reinvestment rate tied to the return earned on new capital (goodwill stripped out to reflect operating efficiency). Every assumption — growth, margins, tax, leverage, convergence timing — is editable, and running the full interactive model adds a 10,000-draw Monte Carlo simulation and WACC-versus-terminal-growth sensitivity heatmaps.
The market price refreshes daily; the DCF fair value updates when Syra Health Corp. Class A Common Stock files a new quarterly or annual report. For educational/informational purposes only — not investment advice. Last updated 2026-08-05.